Pasireotide Diaspartate

门冬氨酸帕瑞肽

Report date: 2022/05/26 17:06:22
NME

Base Information

Drug NamePasireotide Diaspartate
Drug Alias Namepasireotidum帕瑞肽二门冬氨酸盐帕瑞肽pasireotidaSignifor +[9] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionSomatostatin receptor 5 agonistsSomatostatin receptor 3 agonistsSomatostatin receptor 2 agonists +[4] 
TargetsSomatostatin receptor 3Somatostatin receptor 1Somatostatin receptor 5 +[4] 
Therapy Area/IndicationsUveal melanomaMedullary thyroid cancer (MTC)Post-bariatric Hypoglycemia +[36] 
Global Approved IndicationsCushing SyndromePituitary ACTH Hypersecretion
Approved Indications in ChinaCushing Syndrome
Original Approved Country/TerritoryEU
Original Approved Date2012/04/24
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesRecordati Rare Diseases IncNovartis Pharma AgRecordati Spa +[4] 
Inactive CompaniesUtah State UniversityDana-Farber Cancer InstituteRadboud University Medical Center +[16] 
Active IndicationsPost-bariatric HypoglycemiaCushing SyndromePituitary ACTH Hypersecretion +[5] 
Inactive IndicationsUveal melanomaMedullary thyroid cancer (MTC)Gastroenteropancreatic neuroendocrine tumor +[31] 

Other Information

ATC CodeH01CB05
Related LinksWikipediaDrugBankKEGG